Bluebird Bio


bluebird bio submits BLA for sickle cell disease gene therapy

By Rachel Arthur

bluebird bio has announced the submission of a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for lovotibeglogene autotemcel (lovo-cel) gene therapy in patients with sickle cell disease (SCD).


bluebird bio gets green light for Skysona gene therapy in the US

By Rachel Arthur

The US Food and Drug Administration (FDA) has granted Accelerated Approval for bluebird bio’s Skysona (elivaldogene autotemcel), also known as eli-cel, to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral...


bluebird bio plans ‘new nest’ around hybrid work model

By Rachel Arthur

bluebird bio has signed a long-term lease for a 61,000 square foot facility at Assembly Row, Greater Boston: saying the new headquarters has been designed to reflect modern ways of working and deliver significant cost savings.